drugset / Trial / NCT00162773
Effect of Anti-IgE in Non-Allergic Asthma
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to find out if omalizumab is effective in treating non-allergic asthma. The US Food and Drug Administration has approved the use of omalizumab to treat moderate to severe allergic asthma.
Timeline
- Start
- 2005-04
- Primary completion
- 2009-09
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omalizumab | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | Omalizumab | Monoclonal antibody | 375 mg | Subcutaneous |